CCM
THRX

CAAS Capital Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

CAAS Capital Management’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,000
Closed -$190K – 1010
2021
Q4 		$190K Buy
+15,000
New +$226K ﹤0.01% 670

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CAAS Capital Management's THRX Position: Q1 2022 in Review

CAAS Capital Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2022, closing a stake of 15,000 shares — an estimated $190K sold.

CAAS Capital Management first reported a position in THRX in Q4 2021 and held it in 1 quarter. The position peaked at $190K in Q4 2021. 47 funds tracked by Wall St. Rank hold THRX as of Q1 2022.

  • CAAS Capital Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 15,000 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $190K.
  • CAAS Capital Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $190K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.